Artiva Biotherapeutics Inc.
Organization details
- Legal name
- Artiva Biotherapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- SAN Diego
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- ARTV
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001817241
- EIN
- 86-3614316
Board of directors
-
Alison Moore · DirectorSince 2024
-
Brian Daniels · DirectorSince 2024
-
Daniel G. Baker · DirectorSince 2025
-
Elaine K. Sorg · DirectorSince 2026
-
Elizabeth L. Hougen · DirectorSince 2024
-
Fred Aslan · Director · Chief Executive OfficerSince 2024
-
Gines Diego Miralles · DirectorSince 2024
-
Laura Bessen · DirectorSince 2024
-
Laura Stoppel · DirectorSince 2024
- Since 2024
- Since 2024
-
Yong-Jun Huh · DirectorSince 2024
Chief executives
Director election results
Annual meeting of September 8, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
85.3%
-
86.0%
Board connections
7 of this board's directors also sit on 29 other boards. 28 are in the same sector.
-
Acumen Pharmaceuticals Inc. Same sectorvia Laura Stoppel, Peter Kolchinsky and Rajeev M. Shah
-
ARS Pharmaceuticals Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Acrivon Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Bambusa Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Bicara Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Black Diamond Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Climb Bio Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Evommune Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Freenome Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Hemab Therapeutics Holdings Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Jade Biosciences Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Janux Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
LENZ Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Mineralys Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Nkarta Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Parabilis Medicines Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
PepGen Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Septerna Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Sionna Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Solid Biosciences Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
SpyGlass Pharma Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Tyra Biosciences Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Vor Biopharma Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Wave Life Sciences Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Werewolf Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
C4 Therapeutics Inc. Same sectorvia Laura Bessen
- via Alison Moore
-
Contineum Therapeutics Inc. Same sectorvia Gines Diego Miralles
-
Shattuck Labs Inc. Same sectorvia Daniel G. Baker
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $109,120,138
- 21 purchases by 7 insiders
- Sold, last 12 months
- $2,860,196
- 23 sales by 5 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 2, 2026 | Fred Aslan Director, Officer (Chief Executive Officer) | Open-market sale | −62,178 | $4.18 | $259,972 |
| Nov 2, 2026 | Banerjee Subhashis Officer (Chief Medical Officer) | Open-market sale | −1,110 | $4.18 | $4,641 |
| Nov 2, 2026 | Bush Jennifer Officer (COO, CLO, Compliance Officer) | Open-market sale | −8,439 | $4.18 | $35,284 |
| Nov 2, 2026 | Horan Christopher Officer (Chief Tech Operations Officer) | Open-market sale | −10,423 | $4.18 | $43,580 |
| Oct 6, 2026 | Fred Aslan Director, Officer (Chief Executive Officer) | Open-market sale | −23,463 | $7.20 | $168,880 |
| Oct 5, 2026 | Fred Aslan Director, Officer (Chief Executive Officer) | Open-market sale | −61,696 | $6.84 | $421,828 |
| Oct 5, 2026 | Banerjee Subhashis Officer (Chief Medical Officer) | Open-market sale | −1,099 | $6.84 | $7,514 |
| Oct 5, 2026 | Bush Jennifer Officer (COO, CLO, Compliance Officer) | Open-market sale | −8,370 | $6.84 | $57,227 |
| Oct 5, 2026 | Horan Christopher Officer (Chief Tech Operations Officer) | Open-market sale | −10,340 | $6.84 | $70,697 |
| Sep 15, 2026 | Fred Aslan Director, Officer (Chief Executive Officer) | Grant or award | +110,000 | — | — |
| Sep 10, 2026 | Fred Aslan Director, Officer (Chief Executive Officer) | Grant or award | +45,000 | — | — |
| Sep 9, 2026 | Banerjee Subhashis Officer (Chief Medical Officer) | Grant or award | +30,000 | — | — |
| Sep 9, 2026 | Bush Jennifer Officer (COO, CLO, Compliance Officer) | Grant or award | +45,000 | — | — |
| Sep 9, 2026 | Horan Christopher Officer (Chief Tech Operations Officer) | Grant or award | +40,000 | — | — |
| Sep 9, 2026 | Gines Diego Miralles Officer (President & Head of R&D) | Grant or award | +45,000 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Artiva Biotherapeutics Inc.
Who is the CEO of Artiva Biotherapeutics Inc.?
Fred Aslan has been Artiva Biotherapeutics Inc.'s President and CEO since July 2024.
How many directors are on Artiva Biotherapeutics Inc.'s board?
Artiva Biotherapeutics Inc.'s board has 12 directors: Alison Moore, Brian Daniels, Daniel G. Baker, Elaine K. Sorg, Elizabeth L. Hougen, Fred Aslan, Gines Diego Miralles, Laura Bessen, Laura Stoppel, Peter Kolchinsky and 2 others.
Are Artiva Biotherapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Artiva Biotherapeutics Inc. insiders bought $109.1 million of shares in 21 purchases and sold $2.9 million of shares in 23 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="artiva-biotherapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.